Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically/cytologically documented SCCHN, excluding salivary gland primary sites~* 18 years of age or older~* Have evaluable locoregional and/or metastatic disease according to RECIST that is not appropriate for treatment by primary surgical resection or radiotherapy~* Have locoregional and/or metastatic disease that has failed to respond to or relapsed from at least one prior chemotherapy or chemoradiotherapy~* Life expectancy of at least 4 months~* ECOG performance status of 0-2~* Use of effective means of contraception in patients of child-bearing potential~Exclusion Criteria:~* Other malignancy within 5 years except non-melanomatous skin cancer, or carcinoma in situ of the cervix, bladder or head and neck~* Concurrent anticancer therapy other than that of this study~* Treatment with any anticancer drug within 28 days of day 1~* Radiotherapy within 28 days of day 1~* Any unresolved toxicity greater than NCI-CTCAE v 3.0 grade 2 from prior systemic anticancer therapy~* Any prior therapy that targets the ErbB and/or VEGF pathways~* Concurrent therapy with any NSAID~* Known hypersensitivity characterized by acute bronchospasm, urticaria and/or rhinitis to NSAIDs, including aspirin~* Serum creatinine \> 1.5 x ULN~* Abnormal LFTs as outlined in protocol~* Blood pressure \> 150/100mmHg~* Active unstable angina, or myocardial infarction within 6 months~* NYHA Grade II or greater congestive heart failure~* History of stroke within 6 months~* Clinically significant active peripheral vascular disease~* Absolute neutrophil count \< 1000/mm3 or platelets \< 100,000/mm3~* Evidence of bleeding diathesis or coagulopathy.~* Tumor encasing the carotid artery, or other major vessel that in the opinion of the investigators is at risk for tumor-related hemorrhage~* Presence of central nervous system or brain metastases~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for major surgical procedure during the course of the study~* Minor surgical procedures such as fine needle aspiration or core biopsy within 5 days prior to day 1~* Pregnant or lactating~* History of abdominal fistula or intra-abdominal abscess within 6 months~* History of gastrointestinal ulcer, perforation, or bleeding within 6 months~* Serious non-healing wound or ulcer or active uncontrolled infection~* Bone fracture within 28 days~* Active substance abuse, defined by substance abuse of alcohol, cocaine or intravenous drug use within 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib + Bevacizumab (Type: ACTIVE_COMPARATOR): erlotinib plus bevacizumab
- Erlotinib + Sulindac (Type: ACTIVE_COMPARATOR): erlotinib plus sulindac

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues